PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

OL.
18
982

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume contents, Author index
and Subject index to
Volume 18

PERGAMON PRESS OXFORD · NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors
Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology
Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics
Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
R. T. Brittain—*Ware, Hertfordshire*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*London, England*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1983, U.S. $800.00 including postage and insurance. 2 years, 1983/84, U.S. $1520.00.
Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually.
Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to: Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to: Pergamon Press Ltd, Headington Hill Hall, Oxford OX3, 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1982 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Article Fee Code on the first page of an article in this journal indicates the copyright owner's consent that in the U.S.A. copies may be made for personal or internal use provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970. If a code does not appear, copies of the article may be made without charge, provided permission is obtained from the publisher. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon office.

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 18, 1982, Numbers 1–3

CONTENTS

Number 1 PAGE

Digitalis: *K.-O. Haustein* 1

Improved efficacy and safety of theophylline in the control of airways hyperreactivity: *L. Hendeles and M. Weinberger* 91

The need for a rapid and accurate viral diagnosis: *M. L. Landry, D. R. Mayo and G. D. Hsiung* 107

Number 2

Modification of the physiological determinants of cardiac energy expenditure by pharmacological agents: *C. L. Gibbs* 133

Pharmacokinetics and drug distribution during postnatal development: *B. M. Assael* 159

Water and electrolyte exchange during exposure to cold: *M. J. Fregly* 199

Nicotine, resorption and fate: *H. Schievelbein* 233

Calcium ions, drug action and platelet function: *N. G. Ardlie* 249

Calcium ions, drug action and the red cell membrane: *J. S. Wiley and K. E. McCulloch* 271

Number 3

Membrane transport of anthracyclines: *T. Skovsgaard and N. I. Nissen* 293

Cerebrovascular actions of prostaglandins: *R. P. White and A. A. Hagen* 313

Noninvasive chemical methods of estimating pharmacokinetic parameters: *G. G. Graham* 333

Drug treatment and obesity: *J. G. Douglas and J. F. Munro* 351

Role of oxytocin in memory and amnesia: *G. L. Kovács and G. Telegdy* 375

The use of culture techniques in studies on prenatal toxicity: *D. Neubert* 397

AUTHOR INDEX

Ardlie, N. G. 249
Assael, B. M. 159

Douglas, J. G. 351

Fregly, M. J. 199

Gibbs, C. L. 133
Graham, G. G. 333

Hagen, A. A. 313
Haustein, K.-O. 1
Hendeles, L. 91
Hsiung, G. D. 107

Kovács, G. L. 375

Landry, M. L. 107

Mayo, D. R. 107
McCulloch, K. E. 271
Munro, J. F. 351

Neubert, D. 397
Nissen, N. I. 293

Schievelbein, H. 233
Skovsgaard, T. 293

Telegdy, G. 375

Weinberger, M. 91
White, R. P. 313
Wiley, J. S. 271

SUBJECT INDEX

Acetaminophen metabolism and development 185
Acetyl strophanthidin 27
  structure and arrhythmogenicity 53–7
Actodigin, structure and arrhythmogenicity 53–7
Acyclovir 122
Adenosine arabinoside (Ara-A) 121, 122
Adenyl cyclase
  arachidonic acid metabolite regulation 259, 260
  cation regulation 259
  platelet activation 259
Adipose tissue 351
Adriamycin structure 294
Adverse reactions
  anorectic compounds 354–6
  biguanides 363
  digitalis 36–49
Airways hyperreactivity and theophylline 91–102
Amantadine 120, 121
Amikacin metabolism and development 182
Aminoglycosides metabolism and development 181
Amnesia
  model of oxytocin action 386–91
  oxytocin role 381, 382
AMP, cyclic
  calcium influx antagonists 151
  calcium sequestration 260
  cardiac contraction 148, 149
  catecholamine effects 148–50
  cholinergic agents 151
  drugs increasing 263
  platelet activation and calcium 259–61
Amphetamine
  excretion time course 344
  excretion and urine pH 341
  formula 352
  pharmacology 353
Amrinone and cardiac energy expenditure 148
Angina pectoris, digitalis effects 19
Angiotensin system, thermogenic drinking 233, 234
Animal experiments
  alternatives 421–5
  reduction in numbers 424
Anorectic agents 351–68
  administration 359
  adverse reactions 354–6
  clinical efficacy 355, 357, 358
  long-term studies 361
  misuse 357
  patient selection 360
  structures and pharmacology 352–4
  tolerance 359
  withdrawal 360, 361
Anthracycline
  cell content of drug 294, 295
  characteristics 295–7
  DNA binding 296
  efflux mechanism 300–3
  flux determination 297
  human and mouse results 307, 308
  macromolecule coupling in transport 306, 307
  membrane transport 293–308
  resistance of tumor cells 304–6
  structural formulae 294
  transport into cells 297–300
Antiviral drugs 120–3
Arabinose absorption, Woolf plot 161
Arachidonic acid metabolism and cyclic AMP 260, 261
Arginine–vasopressin
  memory effects 378–81
  passive avoidance behavior 380
Arrhythmias
  atrial fibrillation 31, 32
  atrial tachycardia 30, 31
  atrioventricular block 31
  digitalis-induced 28–32
  ectopic ventricular contraction 28, 29
  nodal rhythm 31
  ventricular fibrillation 29, 30
  ventricular tachycardia 29
Arylcarbon hydroxylase, induction in mouse limb buds 419
Aspirin and salivary phenytoin levels 336
Asthma and theophylline serum concentration 94
ATPase
  actomysin 136, 137
  Ca: 136
  Ca–Mg: 273
  heart and brain with cardiac glycosides 38
  Na–K; 136
Atrial muscle fibres, digitalis effects 25
Atrioventricular node, digitalis effects 20–2
Autonomic nervous system, digitalis effects 38–41

Behavior, oxytocin and vasopressin effects 376–8
Biguanides
  adverse drug reaction 363
  clinical pharmacology 362, 363
Blood–brain barrier development 171
Bromovinyldeoxyuridine 123
  herpes virus effects 124

Calcium
  AMP and platelet activation 259–61
  antagonists 262
  conditions of abnormal flux 283–6
  dependent potassium efflux for erythrocytes 281, 282
  and digitalis effects 12, 13
  effects in platelets 253–8
  entry blockers 261, 262
  erythrocyte influx 276–9
  erythrocyte role 271, 272
  erythrocyte shape 279, 280
  membrane protein effects 282, 283
  phospholipase activation 255–8
  platelet plasma membrane binding 252, 253

prostaglandin metabolism 254, 255
translocation and platelet activation 249
Calcium pump
calmodulin stimulation 274, 275
drug effects 275, 276
energy requirements 274
kinetics 272–4
stoichiometry 272–4
Calmodulin
inhibitors 262
platelet activation 258, 259, 262
pump stimulation 274, 275
Carbamazepine, developmental pharmacokinetics 177
Cardiac energy expenditure 133–53
ATPases 135–7
basal metabolism 140, 141
contractility changes 143, 144
determinants 140–3
drug effects 147–53
enthalpy : load relationships 138–40
heart rate 141, 142
initial metabolism 137
load effects 144–7
peripheral vasodilator effects 151–3
recovery metabolism 137, 138
stress-independent energy 142, 143
stroke work 141
thermodynamic system 133–5
wall stress 141, 142
Cardiac glycosides
arrhythmogenic effects 53–7
ATPase effects 58
cardiac energy expenditure 147, 148
genin variation 51
half-maximum inotropic effects 50
QRS prolongation 55
structural features 3
structure–activity relationship 49–58
structures 2
sugar variation 51–3
ventricular and Purkinje fibre survival 54
Cardiac muscle
enthalpy : stress relationship 139
pressure : volume in failure 147
pressure : volume relationship 139, 142
Cardiac output curves and heart condition 146
Cardiac venous return, heart pathology 146
Cardiaoactivity and features 3
Cell culture *see also* culture systems and techniques
embryonic 401–3
virus isolation 109–12
Cerebral vasculature
NSAID effects 320, 321
prostaglandin effects 313–19
prostaglandin synthesis 319, 320
study techniques 314
Cerebral vasospasm, prostaglandins and clinical findings 324, 325
Cerebrospinal fluid and prostaglandins 321–3
Chick embryo test
culture techniques 417
use 416
Chloramphenicol metabolism and development 180, 181
Chlorpromazine, erythrocyte calcium effects 276, 278, 279
Ciclazindol in obesity 365
Cold exposure
body water distribution 199–206
dehydration 199
electrolyte balance 224, 225
hematological effects 202–6
intermediate term 203–6, 211
long term 206–9, 212, 213
plasma electrolytes 217, 218
short term 200–3
tissue electrolytes 217, 219, 220
water balance 221
water gain 220
water loss 221
Contractility and digitalis 5–20
Cotinine excretion 242
Counterimmunoelectrophoresis, viral diagnosis 119
Culture systems *see also* cells
active metabolite testing 421
animal test alternatives 421
definition 397, 398
developmental parameters studied 399, 400
developmental periods 410, 411
embryonic in use 400–15
embryonic tissue 398, 399
metabolic activation of chemicals 418–21
organ 403–5
prenatal toxicity 397–425
tissue 403
whole embryo 410–15
Culture techniques
chick embryos 417
suspension 407–10
Trowell-Type 403
uses 422

Daunomycin structure 294
Daunorubicin
cell uptake and pH 299
cell uptake and sodium azide 298
Ehrlich cell efflux 301, 302
Ehrlich cell uptake 300
tumor cell resistance 304–6
Developmental parameters and culture system study 399, 400
Diabetes, obesity interaction 362
Diagnosis
immunological of virus 114–20
viral 107–26
Diazepam, postnatal age and pharmacokinetics 177, 178
Diethylpropion
pharmacology 353
structure 352
Differentiation 401, 402
Digitalis 1–67
absorption 59
acetylcholine liberation 25
adverse reactions 36–49
allergy 49
autonomic effects 38–41
cardiotonic effects 5, 6
cardiovascular effects 4–36
central nervous effects in animals 36–8
central nervous effects in man 47, 48
coronary circulation 34, 35
diuretic 1
drug interactions 58–63
electrical activity of heart 20–32
elimination methods 64, 65
endocrine effects 49
excretion site 60, 61
force–velocity effects 6
frequency and cardiac activity 25–8

gastrointestinal effects 41–4, 49
glycogen dissociation effects 54
heart effects *in situ* 13–20
history of use 1, 2
-induced arrhythmias 28–32
intoxication 21
ionic, milieu 10–13
left ventricular response 16
metabolic site 59, 60
peripheral vessel effects 32, 33
plant sources 2–4
plasma protein binding 59
poisoning 63, 64
positive inotropic effects 6–8
renal effects 44, 45
splanchnic circulation 34
striated muscle effects 45, 46
temperature dependence 8
target organ response 61–3
total peripheral resistance 33, 34
treatment of poisoning 66, 67
ventricular action potential 20
Digitoxides, LD_{50} in mice 37
Digitoxigen
dissociation rate constants 53
sugar variation 52
Digitoxin, gastric tissue effects 42
Digoxin metabolism and development 183, 184
Diphenylhydantoin, developmental pharmacokinetics 175, 176
Dose, theophylline in asthma 99–101
Drug interactions, digitalis 58–63
Drug metabolism systems
development 165–9
hormonal effects 170
inducibility 170
neonatal imprinting 170, 171
nutritional status 171
phase II reactions 168, 169
Drugs
antiviral 120–3
sensitivity testing 123

Electrolyte exchange, cold exposure 199–207
Embryo culture 410–15
amphibia, fish 417
applicability 414
chicks 415, 416
teratogens studies 412, 413
Embryotoxic compounds
activation mechanisms 418
testing policy 422, 423
Enthalpy–load relationship for cardiac muscle 137–40
Enzyme-linked immunosorbent assay (ELISA)
viral diagnosis 117, 118
Ephedrine in obesity 366
Erythrocyte
calcium extrusion 272
calcium influx 276–9
calcium and membrane 271–87
calcium pump 272–6
cold stores effects 285, 286
facilitated influx 278, 279
lipids and calcium 280
membrane proteins 282, 283
potassium channel 281
potassium efflux 281, 282
properties 271
shape and calcium 279, 280

Evening primrose oil
obesity 365, 366
properties 365

Fenfluramine
obese hypertensives 364
pharmacology 354
plasma levels and weight loss 360
structure 352
Furosemide metabolism and development 183

Gastrointestinal system, absorption inhibition 367, 368
Genin
LD_{50} in mice 37
moiety variation effects 51
structure and arrhythmogenicity 53–7
Gentamicin metabolism and development 181
16α-Gitoxin
a trial reaction 57
inotropic response 8, 9

Heart *see also* cardiac
electrical activity and digitalis 20–32
force–velocity reactions and failure 14
non failing and digitalis 13–17
rhythmicity and contractility 27, 28
Heart failure
digitalis 17–20
inotropic therapy 152
Hereditary hemolytic anemia
calcium flux 284, 285
synonyms 284
His-Purkinje fibre, digitalis effects 23

Immunofluorescence, viral diagnosis 116, 117
Immunoglobulin M detection and viral diagnosis 119, 120
Immunoperoxidase, viral diagnosis 117
Indomethacin metabolism and development 184, 185
Iododeoxyuridine 121
Ischemic heart disease, digitalis effects 19

Kinetic analysis, urinary excretion 342, 343

Liver microsomal system, postnatal developments 165, 166
Lysine–vasopressin, avoidance behavior 376–8

Magnesium and digitalis effects 13
Mazindol
pharmacology 353, 354
structure 352
Membrane transport, anthracyclines 293–308
Memory
oxytocin action 386–90
oxytocin fragment effects 383
oxytocin–vasopressin effects 378–81
sites of oxytocin action 385
Mescaline, postnatal brain 174
Metabolites formation and excretion kinetics 345, 346
Metformin, clinical efficacy 363

Methadone, penetration of postnatal brain 173
Methaqualone, postnatal brain 174
Methylxanthine structure and derivatives 92
Migraine, prostaglandin effects 323, 324
Mixed function oxidase system
  postnatal development 166–8
Morphine, postnatal brain penetration 173

Nicotine 233–44
  absorption mechanism 237, 238
  assay methods 234, 235
  bladder absorption 237
  breast milk 244
  chemical properties 234
  detoxification rate 241, 242
  distribution 238
  early studies 233
  excretion routes 242–4
  lung absorption 236
  metabolic products 239–41
  metabolism and detoxification 239–41
  oral absorption 235, 236
  skin absorption 236
  smokers blood levels 236, 237
  source and blood levels 235
  structure 234
Noninvasive pharmacokinetics, estimations 333–47
Norepinephrine and postnatal brain 173

Obesity *see also* anorectic agents
  absorption inhibition and gut 367
  antidepressants 365
  continuous and intermittant therapy 358
  depression 364
  diabetes interaction 362
  drugs 351–68
  ephedrine 366
  evening primrose oil 365, 366
  hypertension 363, 364
  mortality 351
  thyroid hormones 366, 367
Organ culture
  embryotoxicity 404–7
  glucose utilization 408, 409
  lactate formation 408
  possibilities 405
  suspension 407–10
  toxic compounds 409
Ouabain
  a trial reaction to prolonged infusion 57
  positive inotropic effect 6, 8
  postnatal brain 173, 174
  ventricular automaticity 24
Oxytocin
  amnestic neuropeptide 381
  behavioral effects 376–8
  biodegradation, fragment effects 382–4
  cns effects 375, 376
  cns memory effects 385, 386
  5-HT accumulation 389
  human memory effects 390, 391
  memory and amnesia 375–91
  memory consolidation and retrieval 378–81
  memory mode of action 386, 387
  -peptide interactions 387, 388
  -transmitter interactions 388, 389

Pengitoxin, gastric tissue effects 42
Penicillin metabolism and development 180
Pethidine metabolism and development 186
Pharmacokinetics
  developmental 175–87
  noninvasive estimations 333–47
  postnatal development 159–87
Phenmetrazine
  pharmacology 353
  structure 352
Phenobarbital
  developmental pharmacokinetics 176, 177
  postnatal absorption 161, 174
Phentermine
  pharmacology 353
  structure 352
Phentolamine in heart failure 152
Phenytoin
  plasma and salivary 337
  salivary excretion and aspirin 336
Phosphatidyl inositol cycle, cyclic AMP effects 260, 261
Phospholipase, calcium effects 255–8
Phosphonoformate 122
Plant sources of digitalis 2
Plasma protein, postnatal drug binding 161–3
Platelet activation
  AMP and calcium effects 259–61
  calcium translocation 249–51
  calmodulin 258, 259
  drug effects on calcium 261–3
Platelet-activating factor release 255
Platelet function
  calcium influx 252
  calcium movements 249–53
  calcium regulating scheme 264
  calcium release 252
  contractility activation 253
  intracellular calcium effects 253–8
  membrane calcium binding 252
  membrane fusion 254
Postnatal development
  brain penetration by drugs 172–4
  drug effects 159–87
  drug metabolism systems 165–71
  gastrointestinal drug absorption 160, 161
  growth and body changes 159, 160
  percutaneous drug absorption 160, 161
  pharmacokinetics 175–87
  renal pharmacology 163–5
  serum protein drug binding 161–3
Potassium and digitalis effects 10–12
Prenatal toxicity 397–425
  molecular effects 399
Prolyl–leucyl–glycinamide (PLG), antiamnestic effects 384
Prostaglandins
  cerebral artery synthesis 319, 320
  cerebrospinal fluid 321–3
  cerebrovascular effects 313–27
  cerebrovascular tone 313–15
  cns damage 325–7
  isolated cerebral vessels 318, 319
  metabolism and calcium 254, 255
  topical effects on cerebral vessels 315–18
Prostaglandin synthetase inhibitors and cerebral circulation 320, 321
Purkinje fibres
  digitalis effects 22–5
  modulation of digitalis effects 57, 58

Quinidine 279

Quinine 279

Radioimmunoassay and viral diagnosis 118, 119
Renal excretion mechanism 340–2
Renal function and drugs in postnatal development 63–5
Renal pharmacology, postnatal development 163–5

Salicylates metabolism and development 186
Saliva
  aspirin and phenytoin excretion 336
  clearance calculation 337, 338
  collection 333
  composition 334
  drug concentration uses 338, 339
  drug secretion 333–9
  excretion mechanism 334–7
  sulphonamide secretion 334, 335
Seasonal changes and body fluid compartments 213–17
Sickle cell anemia, calcium fluxes 283, 284
Sinoatrial node, digitalis effects 20–2
Sodium and digitalis effects 10
Structure–activity relationships, cardioactive glycosides 49–58
Subarachnoid hemorrhage, prostaglandin role 324, 325
Sulfonamides
  metabolism and development 182, 183
  salivary secretion 334–6

Temperature and digitalis action 8
Thalassemia, membrane effects 286
Theophylline
  absorption 95–7
  acute bronchodilation dose 98–101
  airways hyperreactivity 91–102
  asthmatic symptoms and serum concentration 94
  bronchospasm blocking 93
  chronic asthma 100–2
  distribution 97
  elimination 98
  forced expiratory volume 93
  intravenous dose 99
  metabolism 97, 98
  metabolism and development 178, 179
  pharmacology 92
  serum concentration and efficacy 92–5
  serum concentration measurement 102
  structure 92
  toxicity and serum concentration 95, 96, 99
  uses 91
Thermodynamic efficiency muscle 135
Thermogenic drinking 221–4
  receptors mediating 223
  renin–angiotensin system 223, 224
  water imbalance in rats 222
Thyroid hormones, obesity treatment 366, 367
Toxicity, digitalis 63, 64
Trifluorothymidine 121
Tumor cells, anthracyclines resistance 304–6

Urine
  cumulative drug excretion 343–5
  drug excretion 339–47
  kinetic analysis of drug excretion 342, 343
  pH 341
  problems in analysis 346, 347

Ventricular function
  left ventricular hypertrophy 15
  response to digitalis 16
Ventricular myocardial fibre, digitalis effects 23, 25
Verapamil, platelet activation 261
Viral diagnosis 107–26
  standard methods 107
  uses in public health 124–6
Virus
  cell culture 109–12
  cytopathic effects 111
  DNA, shape and size 112
  drugs 120–3
  endonuclease mapping 114
  immunological diagnosis 114–20
  isolation 109–11
  microscopy 113, 114
  mini-labs 111
  monkey kidney cell 110
  RNA, shape and size 113
  specimen collection 108
  specimen transport 108, 109

Water exchange
  cold exposure 199–227
  intermediate cold exposure 204, 211
  long term cold exposure 206–9, 212, 213
  seasonal effects 213–17
  short term cold exposure 210

Zimelidine in obesity 365

DL.
18
982